Dr. J.W. Wilmink


Dr. J.W. Wilmink

Scientific staff member (UD)
Main activities
Patient care, Research, Teaching
medical oncology
Focus of research

Upper gastro-intestinal oncology

Breast Cancer

Key publications
  • Molenaar RJ, Radivoyevitch T, Wilmink JW, RE: Colorectal Cancer Incidence Patterns in the United States, 1974-2013. JNCI-J NATL CANCER I 2017;109 (8):djx103 [PubMed]
  • Kordes S, van Berge Henegouwen MI, Hulshof MC, Bergman JJGHM, van der Vliet HJ, Kapiteijn E, van Laarhoven HWM, Richel DJ, Klinkenbijl JHG, Meijer SL, Wilmink JW, Preoperative chemoradiation therapy in combination with panitumumab for patients with resectable esophageal cancer: the PACT study. INT J RADIAT ONCOL 2014;90 (1):190-196 [PubMed]
  • Kordes S, Pollak MN, Zwinderman AH, Mathôt RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ, Wilmink JW, Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. LANCET ONCOL 2015;16 (7):839-847 [PubMed]
  • Deenen MJ, Klümpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, Schellens JHM, Wilmink JW, Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies. INVEST NEW DRUG 2012;30 (4):1557-1565 [PubMed]
  • Rombouts SJ, Mungroop TH, Heilmann MN, van Laarhoven HW, Busch OR, Molenaar IQ, Besselink MG, Wilmink JW, FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Cancer: A Single Centre Cohort Study. J CANCER 2016;7 (13):1861-1866 [PubMed]
All Publications
Research programmes

1. Pancreatic cancer, clinical and translational research. 2. Cancer and metabolism

Dr. J.W. Wilmink

PhD Students
J.W. van Hattum MD MSc
Drs. E.N. Pijnappel

Current research funding
  • Celgene International Sarl
  • Covance International Hodlings B.V.
  • KWF Kankerbestrijding
  • Novartis Pharma BV
  • PAREXEL International (IRL) Limited
  • PAREXEL Nederland B.V.
  • Shire Netherlands B.V.
  • Stichting AMC Foundation
  • ZonMw